CTX-M-Producing Escherichia coli in Lithuania: Associations Between Sites of Infection, Coresistance, and Phylogenetic Groups

Agnė Giedraitienė1, Astra Vitkauskienė2, Virginija Ašmonienė3, Rita Plančiūnienė1, Sandrita Šimonytė1, Alyvydas Pavilonis1, Guillaume Arlet4,5

1Department of Microbiology, Medical Academy, Lithuanian University of Health Sciences, Lithuania,
2Department of Laboratory Medicine, Medical Academy, Lithuanian University of Health Sciences, Lithuania,
3Laboratory of Neuro-oncology and Genetics, Neuroscience Institute, Lithuanian University of Health Sciences, Lithuania,
4Laboratoire de Bacteriologie, UFR de Médecine, Universite Pierre et Marie Curie Paris 6, France,
5Service de Bacteriologie, Hopital Tenon AP-HP, France

Key Words: phylogenetic groups; site of infection; multiresistance; E. coli isolates; CTX-M.

Summary. Increasing resistance of Escherichia coli (E. coli) to antibiotics, especially to the third-generation cephalosporins, has prompted studies on widespread resistance genes such as blaCTX-M and differentiation of E. coli to phylogenetic groups. The aim of this study was to determine the associations between the CTX-M type and the phylogenetic group, the site of infection, and coresistance in Lithuanian E. coli isolates producing β-lactamases.

Material and Methods. A total of 90 E. coli ESBL strains were recovered from the lower respiratory tract, the urinary tract, sterile body sites, wounds, and other body sites between 2008 and 2012. The E. coli isolates resistant to at least 2 antibiotics with different modes of action along with resistance to cefotaxime were considered as multiresistant. The blaCTX-M, blaTEM, blaOXA-1, and blaSHV genes, the phylogenetic groups, and the resistance profiles were analyzed.

Results. Of the 90 isolates, 84 (93.3%) were classified as multiresistant and 6 (6.6%) as resistant. The blaCTX-M-15 gene was the most prevalent gene followed by the blaCTX-M-14 and blaCTX-M-92 genes. The logistic regression analysis revealed the associations between CTX-M-15 and resistance to ceftriaxone, between CTX-M-14 and resistance to cefoxitin, aztreonam, ampicillin/sulbactam, ticarcillin/clavulanic acid, and tobramycin, and between CTX-M-92 and resistance to cefepime, piperacillin/tazobactam, gentamicin, and tobramycin.

Conclusions. The results of this study showed a significant association between CTX-M-15, CTX-M-14, and CTX-M-92 β-lactamases and resistance to some antibiotics as well as CTX-M-14 β-lactamase and phylogenetic group A in the Lithuanian population. The associations between the CTX-M type and the site of infection were not determined.

Introduction
Escherichia coli (E. coli) is the most common microorganism isolated from the sites of extraintestinal, intra-abdominal, community-acquired urinary tract infections and bacteremia (1, 2). Increasing resistance of E. coli to antibiotics, especially to the third-generation cephalosporins, has prompted studies on widespread resistance genes such as blaCTX-M (3) and differentiation of E. coli strains to phylogenetic groups (4). CTX-M β-lactamases encoded by blaCTX-M genes have almost replaced classical TEM- and SHV-type extended-spectrum β-lactamases (ESBLs). There are more than 120 different types of CTX-M β-lactamases that can be divided into 5 groups: CTX-M-1, -2, -8, -9, and -25 (5).
have been identified among the isolates of the Enterobacteriaceae family from 21 Russian hospitals (10) and 17 Polish medical centers (11, 12). In Lithuania, E. coli strains collected during the global tigecycline phase 3 clinical trials were positive for the CTX-M-2, -3, -15, and SHV-12 type β-lactamases (13). Among Lithuanian E. coli strains producing ESBLs, CTX-M-15 β-lactamase and a new specific local variant of CTX-M-92 β-lactamase have been reported to be most prevalent; among Klebsiella pneumoniae strains, CTX-M-15 and SHV-12 β-lactamases (14). CTX-M-2 β-lactamases have also been identified in Lithuania (14), Norway (15), and Russia (16).

To date, few studies have been carried out to establish the associations between a clinical origin of strains, resistance-encoding phenotypes, and phylogenetic groups among E. coli isolates (7, 17, 18). Therefore, the aim of this study was to determine the associations between the CTX-M type and the phylogenetic group, the site of infection, and core-sistance in Lithuanian E. coli isolates producing β-lactamases.

Material and Methods

E. coli Strains. A total of 90 ESBL-producing E. coli with reduced susceptibility to the third-generation cephalosporins were randomly selected from all the ESBL strains collected during the 5-year period from 2008 to 2012. The specimens were recovered from the urinary tract, the lower respiratory tract, wounds, sterile body sites, and other body sites. All the clinical isolates were collected in regional and local hospitals of Lithuania: the Hospital of Lithuanian University of Health Sciences (n=54, 60%), the Republican Panėvėžys Hospital (n=28, 31.1%), the Republican Šiauliai Hospital (n=4, 4.5%), Marijampolė Hospital (n=3, 3.3%), and Alytus County Kudirkos Hospital (n=1, 1.1%).

Laboratory Testing. The isolates were identified using standard microbiological methods, i.e., colony morphology, the API 20E test system (bioMérieux, Marcy l’Etiole, France), or amplification of the region of the 16S rRNA gene (19). The isolates were kept in a tryptic soya broth and 15% glycerol at −20°C until analysis.

Antimicrobial Susceptibility Testing. The initial susceptibility testing to β-lactams was done using the Kirby Bauer disc diffusion method on Muller-Hinton agar (Becton, Dickinson and Company, USA) with cefotaxime and ceftazidime discs (Oxoid, UK). The results were interpreted according to the guidelines of the Clinical Laboratory Standards Institute (CLSI) (20). Commercial broth microdilution panels (GN1F, GN3F, ESB1F, Sensititre; TREK Diagnostic Systems, USA) were used according to the manufacturer’s instructions and were tested against the CLSI quality control strain E. coli ATCC 25922. The minimum inhibitory concentrations (MICs) of the following 17 antibiotics were determined with the Trek Sensititre GN1F and GN3F systems: cefoxitin, ceftriaxone, ceftazidime, cefotaxime, cefepime, aztreonam, piperacillin/tazobactam, ampicillin/subbactam, ticarcillin/clavulanic acid, meropenem, imipenem, gentamicin, amikacin, tobramycin, ciprofloxacin, trimethoprim/sulfamethoxazole, and nitrofurantoin. Confirmation tests for ESBL production were performed by using Trek Sensititre ESB1F panels. The results were interpreted according to the criteria of the CLSI (20). The E. coli isolates resistant to at least 2 antibiotics with different modes of action along with resistance to cefotaxime were considered as multiresistant (MDR).

Detection of β-Lactamase Genes. All the 90 strains included in this study were tested for the blaCTX-M (CTX-M-1, CTX-M-2, and CTX-M-9), blaTEM (21), blaSHV (22), and blaOXA-1 (23) genes by using the polymerase chain reaction (PCR) method. PCR was carried out with a GeneAmp PCR System 9700 thermocycler (Applied Biosystems, France) under the following conditions: initial denaturation at 94°C for 5 minutes, 35 cycles of denaturation at 94°C for 40 seconds, annealing at 55°C for 40 seconds, elongation at 72°C for 1 minute, and final elongation at 72°C for 5 minutes. PCR and the sequencing of amplicons were performed by using the specific primers as described previously (21, 23).

The PCR products were separated by agarose gel electrophoresis on the 1% gel stained with ethidium bromide (10 mg/mL). The length of DNA fragments was determined by using the 100-bp dsDNA fragment standard (GeneRuler 100-bp DNA ladder, New England BioSystems, USA) at a wavelength of 302 nm. Sequencing reactions were carried out with the specific primers used previously for genotyping. Sequencing was performed on an automated sequencer 3130xl (Applied Biosystems, USA). The DNA sequences of interest were checked using the basic local alignment search tool provided by the National Center for Biotechnology Information (24).

Phylogenetic Grouping. Three genetic markers – the chuA and yjaA genes as well as the DNA fragment TspE4.C2 – were used to determine phylogenetic groups by the triplex PCR method. The isolates were assigned to 4 main phylogenetic groups (A, B1, B2, and D) by using a dichotomous decision tree as described by Clermont et al. (4). The fragments after PCR amplification were separated by agarose gel electrophoresis on the 1.5% gel.

Statistical Analysis. Statistical analysis was conducted by using the SPSS (Statistical Package for the Social Sciences, Microsoft Inc., USA) software, version 21.0 for Windows. Categorical variables were compared using the Pearson square or Fisher
exact tests. The logistic regression analysis was used to determine whether a particular CTX-M type had associations with the phylogenetic group, the site of infection, and co-resistance in ESBL-producing E. coli strains. The level of significance was at \( P < 0.05 \).

**Ethical Considerations.** The study was approved by Kaunas Regional Ethics Committee for Biomedical Research (No. BE-2-10).

### Results

**Associations Between CTX-M Genotype and Antimicrobial Resistance.** It was found that 51 E. coli isolates were positive by PCR identification for the \(\text{bla}_{\text{CTX-M-15}}\) gene (56.7%), 12 for \(\text{bla}_{\text{CTX-M-14}}\) (13.3%), 10 for \(\text{bla}_{\text{CTX-M-92}}\) (11%), 3 for \(\text{bla}_{\text{CTX-M-2}}\) (3.3%), 2 for \(\text{bla}_{\text{CTX-M-3}}\) (2.2%), and 1 for \(\text{bla}_{\text{CTX-M-1}}\) (1.1%). A combination of two \(\text{bla}_{\text{CTX-M}}\) genes was identified in 11 isolates: \(\text{bla}_{\text{CTX-14&15}}\) in 3 isolates (3.3%); \(\text{bla}_{\text{CTX-M-2&3}}\) in 3 (3.3%); \(\text{bla}_{\text{CTX-14&441}}\) in 3 (3.3%); and \(\text{bla}_{\text{CTX-M-2&152}}\) and \(\text{bla}_{\text{CTX-M-92}}\) in 1 (each 1.1%). One-fourth (25%) of all the studied isolates were positive for non-ESBL enzymes of TEM (n=23), 22.2% for \(\text{bla}_{\text{OXA-1}}\) (n=20), and 7.7% for both \(\text{bla}_{\text{TEM}}\) and \(\text{bla}_{\text{OXA-1}}\) (n=7). None of the isolates carried the \(\text{bla}_{\text{SHV}}\) gene.

All the 90 isolates were resistant to cefotaxime in vitro. The majority of E. coli isolates were resistant to ampicillin/sulbactam (96.7%), ceftriaxone (90%), and ticarcillin/clavulanic acid (88.9%). The percentages of E. coli isolates resistant to tobramycin, gentamicin, trimethoprim/sulfamethoxazole, aztreonam, and ciprofloxacin were 74.4%, 73.3%, 70%, 66.7%, and 61.1%, respectively. Half (51.5%) of the isolates were resistant to the fourth-generation cephalosporin cefepime. The percentages of E. coli isolates resistant to ceftazidime, cefotaxime, piperacillin/tazobactam, amikacin, and nitrofurantoin were 35.6%, 31.1%, 23.3%, 14.4%, and 13.3%, respectively. None of the tested isolates displayed resistance to imipenem or meropenem.

Of the 90 isolates, 84 (93.3%) were classified as MDR and 6 (6.6%) as resistant only to cefalosporins. Besides, 23 isolates (25.6%) were resistant to 3 different classes of antibiotics, 34 isolates (37.8%) to 4, 22 isolates (24.4%) to 5, and 5 isolates (5.6%) to 6. Multiresistance was most common among the CTX-M-92 isolates (100%, n=10) followed by the CTX-M-15 (94%, n=48) and CTX-M-14 isolates (75%, n=9) (\( P > 0.05 \)). Among nonmultiresistant isolates, 1 isolate was resistant to cefotaxime only, 1 exhibited additional resistance to aztreonam, and 4 isolates had resistance to gentamicin. The distribution of E. coli isolates producing different CTX-M enzymes by antimicrobial resistance is shown in Table 1. The percentage of the CTX-M-92-producing isolates resistant to ceftazidime was significantly greater as compared with the percentages of the isolates producing CTX-M-15 and CTX-M combinations (90% vs. 47.0% and 45.5%; \( P = 0.011 \) and \( P = 0.043 \), respectively). The percentage of the CTX-M-14-producing isolates resistant to aztreonam and tobramycin was significantly lower as compared with the percentages of the isolates producing CTX-M-92 and CTX-M-15 (33.3% vs. 70.6% and 80.0%; \( P = 0.020 \) and \( P = 0.038 \); 100% vs. 41.6% and 76.4%; \( P = 0.023 \) and \( P = 0.005 \), respectively). The CTX-M-92-producing isolates were more frequently resistant to gentamicin than those producing CTX-M combinations (100% vs. 54.5%, \( P = 0.023 \)).

Table 2 summarizes the results of the logistic regression analysis. The binary logistic regression analysis revealed significant associations between CTX-M-15 and resistance to ceftriaxone (OR, 1.2; 95% CI, 1.07–1.37). Moreover, CTX-M-14 was significantly associated with resistance to cefotaxime (OR, 3.8; 95% CI, 1.09–13.29), aztreonam (OR, 0.2; 95% CI, 0.06–0.73), ampicillin/sulbactam (OR, 0.7; 95% CI, 0.01–0.78), ticarcillin/clavulanic acid (OR, 0.2; 95% CI, 0.04–0.72), and tobramycin (OR, 0.2; 95% CI, 0.05–0.66). CTX-M-92 was significantly associated with resistance to cefepime (OR, 10.5; 95% CI, 1.27–86.46), piperacillin/tazobactam (OR, 4; 95% CI, 1.03–15.51), gentamicin (OR, 0.7; 95% CI, 0.12–4.15), and cephalosporin (OR, 13.6; 95% CI, 3.19–57.5).

**Table 1. Distribution of E. coli Isolates Producing Different CTX-M Enzymes by Antimicrobial Resistance**

| Antibiotic                              | CTX-M-15 | CTX-M-14 | CTX-M-92 | Other | Combination |
|-----------------------------------------|----------|----------|----------|-------|-------------|
|                                        | N=51     | N=12     | N=10     | N=6   | N=11        |
| Ceftriaxone                             | 43 (84.3)| 12 (100.0)| 10 (100.0)| 5 (83.4)| 11 (100.0)  |
| Cefoxitin                               | 14 (27.5)| 7 (58.3) | 2 (20.0) | 1 (16.7)| 4 (36.4)    |
| Cefazidime                              | 21 (41.2)| 2 (16.7) | 3 (30.0) | 1 (16.7)| 5 (45.5)    |
| Cefepime                                | 24 (47.0)| 6 (50.0) | 9 (90.0) | 2 (33.3)| 5 (45.5)    |
| Aztreonam                               | 36 (70.6)| 4 (33.3) | 8 (80.0) | 4 (66.7)| 8 (72.7)    |
| Ampicillin/sulbactam                    | 50 (98.0)| 10 (83.4)| 10 (100.0)| 6 (100.0)| 11 (100.0)  |
| Ticarcillin/clavulanic acid             | 46 (90.2)| 8 (66.7) | 10 (100.0)| 6 (100.0)| 10 (91.0)   |
| Piperacillin/tazobactam                 | 11 (21.6)| 1 (8.3)  | 5 (50.0) | 1 (16.7)| 3 (27.7)    |
| Gentamicin                              | 37 (72.5)| 8 (66.7) | 10 (100.0)| 5 (83.4)| 6 (54.5)    |
| Tobramycin                              | 39 (76.4)| 5 (41.6) | 10 (100.0)| 5 (83.4)| 8 (72.7)    |
| Amikacin                                | 6 (11.8) | 1 (8.3)  | 3 (30.0) | 2 (33.0)| 1 (9.0)     |
| Ciprofloxacin                           | 33 (65.0)| 6 (50.0) | 6 (60.0) | 3 (50.0)| 7 (63.6)    |
| Trimethoprim/sulfamethoxazole           | 35 (68.6)| 7 (58.3) | 6 (60.0) | 6 (100.0)| 9 (81.8)    |
| Furantoin                               | 7 (13.7) | 1 (8.3)  | 1 (10.0) | 1 (16.7)| 2 (18.0)    |

Medicina (Kaunas) 2013;49(9)
95% CI, 0.60–0.80), and tobramycin (OR, 0.7; 95% CI, 0.62–0.82).

**Distribution of *E. coli* Isolates Carrying **bla** _CTX-M_ Genes According to Phylogenetic Groups and Infection Sites.** The distribution of the ESBL-producing *E. coli* isolates carrying different **bla** _CTX-M_ genes according to the phylogenetic groups and infection sites is shown in Table 3. The isolates investigated in our study were assigned to 3 main phylogenetic groups: A, B2, and D. The results showed that 39 isolates (43.3%) belonged to phylogenetic group B2, 26 isolates (28.9%) were assigned to group A, and 25 (27.8%) belonged to group D (P<0.05). None of the isolates were assigned to group B1. The binary logistic regression analysis showed a significant association only between CTX-M-14 and phylogenetic

---

**Table 2. Association Between the Type of CTX-M and Antibiotic Resistance Among *E. coli* Isolates**

| Antibiotic Resistance | CTX-M-15 OR (95% CI) | P | CTX-M-14 OR (95% CI) | P | CTX-M-92 OR (95% CI) | P | Other OR (95% CI) | P | Combination OR (95% CI) | P |
|-----------------------|---------------------|---|---------------------|---|---------------------|---|-------------------|---|---------------------|---|
| Ceftriaxone            | 1.2 (1.07–1.37)     | 0.005 | NA                 | NA | NA                 | NA | NA                | NA | NA                 | NA |
| Cefoxitin              | 0.6 (0.26–1.55)     | NS | 3.8 (1.09–13.29)   | 0.035 | 1.2 (0.10–2.62)   | NS | 1.1 (0.60–0.50)   | NS | 2.5 (1.35–4.89)    | NS |
| Ceftazidime            | 1.7 (0.68–4.06)     | NS | 0.3 (0.67–1.56)    | NS | 0.8 (0.18–3.14)   | NS | 0.4 (0.05–4.07)   | NS | 1.6 (0.45–5.74)    | NS |
| Cefepime               | 0.6 (0.27–1.45)     | NS | 0.9 (0.28–3.20)    | NS | 10.5 (1.27–86.46) | 0.009 | 0.6 (0.09–3.91)   | NS | 0.8 (0.22–2.74)    | NS |
| Aztreonam              | 1.57 (0.65–3.79)    | NS | 0.2 (0.06–0.73)    | 0.013 | 2.2 (0.44–11.06)  | NS | 0.8 (0.12–4.75)   | NS | 1.4 (0.35–5.76)    | NS |
| Ampicillin/sulbactam   | 2.8 (0.25–32.44)    | NS | 0.7 (0.01–0.78)    | 0.046 | 0.9 (0.92–1.01)   | NS | 0.9 (0.93–1.01)   | NS | NA                 | NA |
| Ticarcillin/clavulanic acid | 1.4 (0.38–5.32) | NS | 0.2 (0.04–0.72)    | 0.010 | NA                 | NA | NA                | NA | 1.3 (0.15–11.26)   | NS |
| Piperacillin/tazobactam| 0.8 (0.28–2.01)     | NS | 0.3 (0.32–1.27)    | NS | 4 (1.03–15.51)    | 0.034 | 0.8 (0.09–7.69)   | NS | 1.2 (0.30–5.29)    | NS |
| Gentamicin             | 0.97 (0.38–2.49)    | NS | 0.7 (0.19–2.54)    | NS | 0.7 (0.60–0.80)   | 0.037 | 1.5 (0.16–13.98)  | NS | 0.4 (0.10–1.39)    | NS |
| Tobramycin             | 1.4 (0.52–3.52)     | NS | 0.2 (0.05–0.66)    | 0.010 | 0.7 (0.62–0.82)   | 0.043 | 1.4 (0.15–13.18)  | NS | 0.9 (0.22–3.74)    | NS |
| Amikacin               | 0.58 (0.18–1.88)    | NS | 0.5 (0.06–4.24)    | NS | 3 (0.67–13.33)    | NS | 4.3 (0.67–29.93)  | NS | 0.6 (0.06–4.77)    | NS |
| Ciprofloxacin          | 1.2 (0.54–2.97)     | NS | 0.6 (0.18–2.00)    | NS | 0.9 (0.25–3.63)   | NS | 0.9 (0.15–6.00)   | NS | 1.1 (0.30–4.18)    | NS |
| Trimethoprim/sulfamethoxazole | 0.9 (0.37–2.29) | NS | 0.6 (0.16–1.92)    | NS | 0.6 (0.16–2.35)   | NS | NA                | NA | 2.1 (0.42–10.36)   | NS |
| Furantoin              | 1.0 (0.29–3.52)     | NS | 0.6 (0.07–4.73)    | NS | 0.6 (0.08–6.05)   | NA | 1.7 (0.17–16.46)  | NS | 1.5 (0.29–8.14)    | NS |

NS, not significant; NA, not applicable.

**Table 3. Distribution of ESBL-producing *E. coli* Isolates Carrying Different **bla** _CTX-M_ Genes According to the Phylogenetic Groups and Infection Sites**

| Characteristic | CTX-M-15 N=51 | CTX-M-14 N=12 | CTX-M-92 N=10 | Other N=6 | Combination N=11 | Total |
|----------------|---------------|---------------|---------------|-----------|------------------|-------|
| Phylogenetic group |               |               |               |           |                  |       |
| B2             | 20 (39.2)     | 6 (50.0)      | 7 (70.0)      | 1 (16.7)  | 5 (45.4)         | 39 (43.3) |
| D              | 13 (25.5)     | 6 (50.0)      | 2 (20.0)      | 1 (16.7)  | 3 (27.3)         | 25 (27.8) |
| A              | 18 (35.3)     | 0 (0.0)       | 1 (10.0)      | 4 (66.6)  | 3 (27.3)         | 26 (28.9) |
| Infection site |               |               |               |           |                  |       |
| Urinary tract  | 22 (43.1)     | 4 (33.4)      | 1 (10.0)      | 0 (0.0)   | 4 (36.4)         | 31 (34.4) |
| Lower respiratory tract | 11 (21.6) | 3 (25.0) | 4 (40.0) | 2 (33.3) | 3 (27.3) | 23 (25.6) |
| Wounds         | 10 (19.6)     | 1 (8.3)       | 1 (10.0)      | 2 (33.3)  | 3 (27.3)         | 17 (18.9) |
| Sterile body site | 6 (11.8) | 3 (25.0) | 3 (30.0) | 1 (16.7)  | 0 (0.0)          | 13 (14.4) |
| Other body site | 2 (3.9)       | 1 (8.3)       | 1 (10.0)      | 1 (16.7)  | 1 (9.0)          | 6 (6.7)   |
group A (OR, 0.56; 95% CI, 0.45–0.70, P=0.039); no significant associations between other CTX-M and phylogenetic groups were documented.

The greatest percentage of the E. coli isolates producing CTX-M-type β-lactamases in our study were isolated from the urinary tract (34.4%) followed by the lower respiratory tract (25.6%), wounds (18.9%), sterile body sites (14.4%), and other body sites (6.7%) (P>0.05). The logistic regression analysis revealed no significant associations between a particular CTX-M type and infection sites.

Discussion

To our knowledge, this study was the first that was aimed at determining associations between the CTX-M type and the phylogenetic group, the site of infection, and co-resistance in E. coli isolates-producing β-lactamases.

Our results showed that the most common CTX-M β-lactamase among the E. coli isolates, collected during the period of 5 years, was CTX-M-15 followed by CTX-M-14 and CTX-M-92. In 2010, the most prevalent CTX-M β-lactamase in the E. coli isolates was the same CTX-M-15 (36%) followed by CTX-M-92 (17%) and CTX-M-14 (13%) (14). The results of our study are consistent with the global distribution of CTX-M-15 and CTX-M-14 (6). In agreement with other studies (14, 25), our study showed that the E. coli isolates producing CTX-M also encoded narrow-spectrum β-lactamases TEM or OXA-1. Moreover, we determined that the E. coli isolates could carry both TEM and OXA-1 β-lactamases. None of our E. coli isolates were found to carry the blaSHV gene, as in the study by Dahmen et al. (25).

The isolates producing CTX-M β-lactamases also exhibit co-resistance to non-β-lactam antibiotics. According to the study by Östholf Balkhed et al. (26), 68% of the CTX-M-producing E. coli isolates were multiresistant. Our study showed a higher percentage of multiresistant strains (93.3%). This could be influenced by the fact that the isolates for analysis were sent to the Department of Microbiology from the biggest hospitals in Lithuania where patients with the most severe illnesses are treated.

This study demonstrated that the E. coli isolates producing CTX-M-14 were more susceptible to ciprofloxacin, gentamicin, and tobramycin than the isolates carrying CTX-M-15 and CTX-M-92 β-lactamases. These results are consistent with the results of the study done by Östholf Balkhed et al. (26). According to this study, the isolates belonging to CTX-M group 9 were more susceptible to ciprofloxacin, gentamicin, and tobramycin than those belonging to CTX-M group 1 (26). All our isolates carrying CTX-M-92 genes were resistant to ampicillin/sulbactam, ticarcillin/clavulanic acid, gentamicin, and tobramycin (100%). The majority of our isolates were susceptible to furantoin and amikacin, which confirms the results of the study by Östholf Balkhed et al. (26). One-third of the isolates producing CTX-M-92 and other β-lactamases (CTX-M-1, -2, and -3) were resistant to amikacin. The results of our study also demonstrated that CTX-M-92 was associated with 10-fold greater resistance to cefepime and nearly 1.5-fold lower resistance to tobramycin and gentamicin.

To our knowledge, this study was the first to report the distribution of Lithuanian ESBL-producing E. coli clinical isolates according to the phylogenetic groups. It was determined that the CTX-M E. coli isolates most frequently belonged to group B2 (43%). Interestingly, our results are similar to those obtained in the French studies by Branger et al. (17) and Brisse et al. (27), who reported the corresponding percentages of 39.4% and 42%, respectively. Nearly one-third of our isolates belonged to phylogenetic group A and D (29% and 28%, respectively), whereas in the study by Brisse et al. (27), 29% of the studied E. coli isolates were assigned to phylogenetic group A and 16% to phylogenetic group D. Among ESBL-producing strains, none of the 4 groups were associated with one particular type of CTX-M (28). However, our study showed a significant association between the CTX-M-14 type and phylogenetic group A. According to the authors, the frequency of a phylogenetic group among isolates might be related to a geographical area, differences in the characteristics of the host population, and differences in sampling methods (18).

It has been reported that CTX-M E. coli strains are mainly isolated from the urinary tract (17), less frequently from the lower respiratory tract, sterile body sites, wounds, and other body sites (1). The greatest percentages of the strains producing CTX-M-type β-lactamases were isolated from the urinary tract except for the isolates producing CTX-M-92 and other CTX-M β-lactamases (CTX-M-1, CTX-M-2, and CTX-M-3). Finally, we failed to determine significant associations between the CTX-M type and infection sites.

Conclusions

A better understanding of the relationship between CTX-M β-lactamases and other associated factors would ease decisions regarding the empirical treatment of infections caused by ESBL E. coli. The results of this study showed a significant association between CTX-M-15, CTX-M-14, and CTX-M-92 β-lactamases and resistance to some antibiotics as well as CTX-M-14 β-lactamase and phylogenetic group A in the Lithuanian population. The associations between the CTX-M type and the site of infection were not determined.
Acknowledgments

The authors would like to thank Dr. V. Tatarūnas for reading the manuscript.

This work was supported by the Pierre and Marie Curie Faculty of Medicine, University of Paris 6, France, the Embassy of France in Lithuania, the French Institute in Lithuania, the Research Council of Lithuania, and the Open Foundation of the Lithuanian University of Health Sciences.

Statement of Conflict of Interest

The authors state no conflict of interest.

References

1. Nicolas-Chanoine MH, Jarlier V, Robert J, Arlet G, Drieux L, Leflon-Guibout V, et al. Patient’s origin and lifestyle associated with CTX-M-producing Escherichia coli: a case-control-control study. PLoS One 2012;7:e39498.

2. Nyberg SD, Osterblad M, Hakanen AJ, Huovinen P, Jälva J, Resistance TF. Detection and molecular genetics of extended-spectrum β-lactamases among cefuroxime-resistant Escherichia coli and Klebsiella spp. isolates from Finland, 2002–2004. Scand J Infect Dis 2007;39:417-24.

3. Canton R, Coque TM. The CTX-M β-lactamase pandemic. Curr Opin Microbiol 2006;9:466-75.

4. Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol 2000;66:4553-9.

5. Tamang MD, Nam H-M, Jang G-C, Kim S-R, Chae MYC, Jung SC, et al. Molecular characterization of extended-spectrum β-lactamase-producing and plasmid-mediated AmpC-β-lactamase-producing Escherichia coli isolated from stray dogs in South Korea. Antimicrob Agents Chemother 2012;56:2705-12.

6. Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, et al. CTX-M changing the face of ESBLs in Europe. J Antimicrob Chemother 2007;59:165-74.

7. Bukh AS, Schonheyder HC, Emmer D. Genetic background of Escherichia coli and Klebsiella pneumoniae isolates from Polish hospitals. Antimicrob Agents Chemother 2008;52:259-66.

8. Bradford PA, Yang Y, Sahm I, Grope G, Gardowska D, Storch G. CTX-M-5, a novel cefotaxime-hydrolysing β-lactamase from an outbreak of Salmonella typhimurium in Latvia. Antimicrob Agents Chemother 1998;42:1980-4.

9. Edelstein M, Pimkina M, Dmitrachenko T, Semenov V, Bastholm S, Rosley P. Escherichia coli phylogenetic groups are associated with site of infection and level of antibiotic resistance in community-acquired bacteraemia: a 10-year population-based study in Denmark. J Antimicrob Chemother 2009;64:163-8.

10. Bradford PA, Yang Y, Sahm I, Grope G, Gardowska D, Storch G. CTX-M-5, a novel cefotaxime-hydrolysing β-lactamase from an outbreak of Salmonella typhimurium in Latvia. Antimicrob Agents Chemother 1998;42:1980-4.

11. Edelstein M, Pimkina M, Dmitrachenko T, Semenov V, Kozlova N, Gladin D, et al. Multiple outbreaks of nosocomial Salmonellosis in Russia and Belarus caused by a single clone of Salmonella enterica serovar Typhimurium producing an extended-spectrum β-lactamase. Antimicrob Agents Chemother 2004;48:2808-15.

12. Edelstein M, Pimkina M, Palagin I, Edelstein I, Strachounski L. Prevalence and molecular epidemiology of CTX-M extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Russian hospital. Antimicrob Agents Chemother 2003;47:3724-32.

13. Bariang A, Fiett J, Madec JY, Ben Redjeb S, et al. Clonal dissemination of a CTX-M-15-producing clonical isolates of Escherichia coli reveals the spread of multidrug-resistant ST131 (O25:H4) and ST964 (O102:H6) strains in Norway. APMIS 2009;117:526-36.

14. Fusurova NK, Parymnchuk SD, Abaev IV, Kovalev YN, Shishkova NA, Pecherskikh EJ, et al. Genetic environments of bla(CTX-M) genes located on conjugative plasmids of Enterobacteriaceae nosocomial isolates collected in Russia within 2003–2007. Antibiot Khimioter 2010;55:3-10.

15. Branger C, Zamfir O, Geoffroy S, Laurans G, Arlet G, Thien HV, et al. Genetic background of Escherichia coli and extended-spectrum β-lactamase type. Emerg Infect Dis 2005;11:54-61.

16. Martinez JA, Soto S, Fabrega A, Almelia M, Mensa J, Soriano A, et al. Relationship of phylogenetic background, biofilm production, and time to detection of blood culture with clinical variables and prognosis associated with Escherichia coli bacteremia. J Clin Microbiol 2006;44:1468-74.

17. Sabat G, Rose P, Hickey WJ, Harkin JM. Selective and sensitive method for PCR amplification of Escherichia coli 16S rRNA genes in soil. Appl Environ Microbiol 2000;66:844-9.

18. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Approved standard M2-A9 and M7-A7. Clinical and Laboratory Standards Institute. Pennsylvania, USA; 2008.

19. Eckert C, Gautier V, Arlet G. DNA sequence analysis of the genetic environment of various blaCTX-M genes. J Antimicrob Chemother 2006;57:14-23.

20. Lavollay M, Mamlouk K, Frank T, Akpabie A, Burghoffer B, Ben Redjeb S, et al. Clonal dissemination of a CTX-M-15 beta-lactamase-producing Escherichia coli strain in the Paris area, Tunis, and Bangui. Antimicrob Agents Chemother 2006;50:2433-8.

21. Basic local alignment search tool. Available from: URL: http://blast.ncbi.nlm.nih.gov/Blast.cgi

22. Dahmen S, Henni M, Chatre P, Madec JY. Characterization of blaCTX-M IncFII plasmids and clones of Escherichia coli from pets in France. J Antimicrob Chemother 2013;68:2797-801.

23. Östholt Balkhed Å, Tärnberg M, Monstein HJ, Hällgren A, Hanberger H, Nilsson LE. High frequency of co-resistance in CTX-M-producing Escherichia coli to non-beta-lactam antibiotics, with the exceptions of amikacin, nitrofurantoin, colistin, tigecycline, and fosfomycin, in a county of Sweden. scand J Infect Dis 2013;45:271-8.

24. Brisse S, Diancourt L, Laoüénan C, Vigan M, Caro V, Arlet G, et al. Phylogenetic distribution of CTX-M- and extended-spectrum β-lactamase-producing Escherichia coli isolates: group B2 isolates, except clone ST131, rarely produce CTX-M enzymes. J Clin Microbiol 2012;50:2974-81.

25. Ruppe E, Hem S, Lath S, Gautier V, Arrey F, Sartihou JL, et al. CTX-M-β-lactamases in Escherichia coli from community-acquired urinary tract infections, Cambodia. Emerg Infect Dis 2009;15:741-8.